Reynard, Stéphanie http://orcid.org/0000-0002-8508-5167
Carnec, Xavier http://orcid.org/0000-0001-7858-1675
Picard, Caroline http://orcid.org/0000-0002-9214-3900
Borges-Cardoso, Virginie
Journeaux, Alexandra
Mateo, Mathieu http://orcid.org/0000-0001-7941-0245
Germain, Clara
Hortion, Jimmy
Albrecht, Laure
Perthame, Emeline http://orcid.org/0000-0002-8266-5908
Pietrosemoli, Natalia
Vallvé, Audrey
Barron, Stéphane
Duthey, Aurélie
Lacroix, Orianne
Jourjon, Ophélie
Moroso, Marie
Fellmann, Lyne
Moreau, Pierre-Henri
Daniau, Maïlys
Legras-Lachuer, Catherine
Dirheimer, Manon
Carbonnelle, Caroline
Raoul, Hervé http://orcid.org/0000-0002-4241-3255
Baize, Sylvain http://orcid.org/0000-0002-3234-7477
Funding for this research was provided by:
Institut Pasteur
Article History
Received: 11 April 2022
Accepted: 27 October 2022
First Online: 5 January 2023
Competing interests
: The authors declare no competing interests. The MOPEVAC vaccine platform described in this study is protected by US patent 62/245,631; the authors listed as co-inventors are S.R., S. Baize, X.C., M. Mateo and A.J.
Free to read: This content has been made available to all.